LUND, Sweden--(BUSINESS WIRE)--
•Phase II data presented in May shows that the antithrombotic effect of TB-402 is better than enoxaparin, the current standard treatment.
•In May BioInvent and ThromboGenics achieved a milestone corresponding to EUR 10 million when development partner Roche launched a new clinical study with the product candidate TB-403.
•Reorganisation will give greater focus on the company’s proprietary drug development. Adapted manufacturing capacity to in house needs, reduces fixed costs by around SEK 15 million on an annual basis.
•In March BioInvent entered into a partnership with Human Genome Sciences to develop and commercialise therapeutic antibodies.
•A directed new share issue that raised SEK 150 million for the company before transaction costs was implemented in February.
•Net revenues for January - June 2010: SEK 63.1 million (47.1).
•Loss after tax for January - June 2010 amounted to SEK -60.7 million (-88.2) and the loss after tax per share was SEK -1.01 (-1.59).
•Current investments together with cash and bank as of 30 June 2010: SEK 138.7 million, excluding share of milestone payments for TB-403 received in July, (150.5).
•Cash flow from current operations and investment activities for January – June 2010: SEK -89.7 million (-61.9).
